J Mov Disord.
2024 Oct;17(4):369-386. 10.14802/jmd.24140.
Evidence-Based Review on Symptomatic Management of Huntington’s Disease
- Shin JH
1 - Yang HJ2
- Ahn JH3
- Jo S4
- Chung SJ5
- Lee JY6
- Kim HS7
- Kim M1
- on behalf of the Korean Huntington’s Disease Society1
- Affiliations
-
- 1Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
- 2Department of Neurology, Ulsan University Hospital, Ulsan, Korea
- 3Department of Neurology, Seoul Samsung Medical Center, Seoul, Korea
- 4Department of Neurology, Seoul Asan Medical Center, Seoul, Korea
- 5Department of Neurology, Yongin Severance Hospital, Yonsei University Health System, Yongin, Korea
- 6Department of Neurology, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea
- 7Department of Neurology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea
- KMID: 2560192
- DOI: http://doi.org/10.14802/jmd.24140
Abstract
- Huntington’s disease (HD) is a neurodegenerative disorder characterized by motor, behavioral, and cognitive impairments and significant impacts on patient quality of life. This evidence-based review, conducted by the Korean Huntington Disease Society task force, systematically examines current pharmacological and nonpharmacological interventions for symptomatic management of HD. Following PRISMA guidelines, databases were searched for studies up to August 2022 that focused on 23 symptoms across four domains: motor, neuropsychological, cognition, and others. This review provides a comprehensive and systematic approach to the management of HD, highlighting the need for more high-quality clinical trials to develop robust evidence-based guidelines.
